Search
for

    Learn

    3 / 3 results

      learn Tretinoin

      the gold standard retinoid in dermatology that's also helpful for hair regrowth alongside Minoxidil

      learn Valproic acid

      an anticonvulsant repurposed for hair loss via histone inhibition

    Research

    5 / 1000+ results

    Community Join

    5 / 262 results

      community why hair restoration has not been progressed for last 20 years?

      in Chat  34 upvotes 1 year ago
      The conversation discusses the lack of significant advancements in hair loss treatments beyond finasteride and minoxidil, questioning if hair restoration technology has reached a dead end. Hair transplant technology has improved, but new medications face challenges with market entry, cost, accessibility, and long-term effectiveness.

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  44 upvotes 4 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.

      community FINASTRIDE and switch to DUTASTRIDE, my experience

      in Progress Pictures  135 upvotes 2 months ago
      The user shared their experience with Finasteride and Dutasteride for hair loss. They initially had success with Finasteride but switched to Dutasteride after experiencing shedding, which continued, and are now considering a hair transplant.

      community Proof that finasteride messes with neurosteroids

      in Research/Science  230 upvotes 4 months ago
      Finasteride can impact neurosteroids, potentially causing depression and other side effects in some users. Despite these concerns, many continue using it for hair loss, with some switching to topical applications to mitigate side effects.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  40 upvotes 1 year ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.